Study | No. of Patients | Treatment | Intracranial Bleeding Events | Recanalization |
---|---|---|---|---|
Cronqvist et al3 | 19 | IA urokinase | 3 (16%) | 10 (53%) |
Fourie and Duncan5 | 1 | IV abciximab | 0 (0%) | 1 (100%) |
Ng et al8 | 1 | IV abciximab | 0 (0%) | 1 (100%) |
Cloft et al9 | 4 | IV abciximab | 0 (0%) | 2 (50%) |
Kwon et al10 | 3 | IA abciximab | 0 (0%) | 3 (100%) |
Alexander et al11 | 1 | IV abciximab | 0 (0%) | 1 (100%) |
Mounayer et al13 | 13 | IA abciximab | 0 (0%) | 12 (92%) |
Bendok et al14 | 1 | IV abciximab | 0 (0%) | 1 (100%) |
Song et al15 | 7 | IA abciximab | 0 (0%) | 5 (71%) |
Note:—IA indicates intra-arterial; IV, intravenous.